Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Social, psychological, and substance use characteristics of U.S. adults who use kratom: Initial findings from an online, crowdsourced study.
Kirsten E. Smith, Kelly E. Dunn, Oliver Grundmann, et al.
Experimental and Clinical Psychopharmacology (2021) Vol. 30, Iss. 6, pp. 983-996
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations
Christopher R. McCurdy, Abhisheak Sharma, Kirsten E. Smith, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 2, pp. 131-142
Closed Access | Times Cited: 18
Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use
Kirsten E. Smith, Jeffrey M. Rogers, Destiny Schriefer, et al.
Drug and Alcohol Dependence (2021) Vol. 226, pp. 108879-108879
Open Access | Times Cited: 56
Understanding Kratom Use: A Guide for Healthcare Providers
Marc T. Swogger, Kirsten E. Smith, Albert Garcia‐Romeu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 52
Kratom use as more than a “self-treatment”
Kirsten E. Smith, Kelly E. Dunn, Jeffrey M. Rogers, et al.
The American Journal of Drug and Alcohol Abuse (2022) Vol. 48, Iss. 6, pp. 684-694
Closed Access | Times Cited: 37
Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories
Kirsten E. Smith, Jeffrey M. Rogers, Kelly E. Dunn, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 36
Assessment of Kratom Use Disorder and Withdrawal Among an Online Convenience Sample of US Adults
Kirsten E. Smith, Kelly E. Dunn, Jeffrey M. Rogers, et al.
Journal of Addiction Medicine (2022) Vol. 16, Iss. 6, pp. 666-670
Open Access | Times Cited: 32
Examining the paradoxical effects of kratom: a narrative inquiry
Kirsten E. Smith, Jeffrey D. Feldman, Kelly E. Dunn, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 20
Growing pains with kratom: experiences discussed in subreddits contrast with satisfaction expressed in surveys
Jeffrey M. Rogers, Kayla Colvin, David H. Epstein, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Correlations of kratom (Mitragyna speciosa Korth.) use behavior and psychiatric conditions from a cross-sectional survey.
Oliver Grundmann, Charles A. Veltri, Sara Morcos, et al.
Experimental and Clinical Psychopharmacology (2023) Vol. 31, Iss. 5, pp. 963-977
Open Access | Times Cited: 14
At least four groups of kratom consumers in the United States: latent-class analysis of motivations for kratom use
Katherine Hill, Jeffrey M. Rogers, Oliver Grundmann, et al.
The American Journal of Drug and Alcohol Abuse (2025), pp. 1-13
Open Access
Editorial on Special Issue “Pharmacokinetics, Pharmacodynamics, and Drug Interactions”
Zhu Zhou
Pharmaceutics (2025) Vol. 17, Iss. 2, pp. 266-266
Open Access
Systematic Review of Clinical Case Reports Involving Tianeptine Products: “Gas Station Heroin” Hype or Fact?
Kirsten E. Smith, Jeffrey D. Feldman, Caroline Freinberg, et al.
Current Addiction Reports (2025) Vol. 12, Iss. 1
Closed Access
Omissions, Ambiguities, and Underuse of Causal Assessment Tools: a Systematic Review of Case Reports on Patients Who Use Kratom
Jeffrey D. Feldman, Destiny Schriefer, Kirsten E. Smith, et al.
Current Addiction Reports (2023) Vol. 10, Iss. 2, pp. 293-303
Closed Access | Times Cited: 11
Kratom’s Emergence and Persistence Within the US Polydrug Epidemic
Kirsten E. Smith, Jeffrey M. Rogers, Jeffrey D. Feldman
Current Addiction Reports (2023) Vol. 10, Iss. 2, pp. 262-271
Open Access | Times Cited: 10
Novel methods for the remote investigation of emerging substances: Application to kratom.
Kirsten E. Smith, Jeffrey D. Feldman, Kelly E. Dunn, et al.
Experimental and Clinical Psychopharmacology (2023) Vol. 32, Iss. 2, pp. 215-227
Open Access | Times Cited: 10
Cannabidiol and mitragynine exhibit differential interactive effects in the attenuation of paclitaxel-induced mechanical allodynia, acute antinociception, and schedule-controlled responding in mice
Yuma T. Ortiz, Joshua A. Bilbrey, Jasmine S. Felix, et al.
Pharmacological Reports (2023) Vol. 75, Iss. 4, pp. 937-950
Closed Access | Times Cited: 10
Correlations of kratom (Mitragyna speciosa Korth.) tea bag preparations and reported pharmacological effects
Oliver Grundmann, Katherine Hill, Everest Al Barzanji, et al.
Journal of Ethnopharmacology (2023) Vol. 317, pp. 116779-116779
Closed Access | Times Cited: 9
Pharmacokinetic Interaction of Kratom and Cannabidiol in Male Rats
Erin C. Berthold, Shyam H. Kamble, Raju S. Kanumuri, et al.
Pharmaceutics (2024) Vol. 16, Iss. 3, pp. 318-318
Open Access | Times Cited: 3
Need for Clarity and Context in Case Reports on Kratom Use, Assessment, and Intervention
Kirsten E. Smith, Kelly E. Dunn, David H. Epstein, et al.
Substance Abuse (2022) Vol. 43, Iss. 1, pp. 1221-1224
Closed Access | Times Cited: 14
Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature
Cornel N. Stanciu, Saeed Ahmed, Samantha A. Gnanasegaram, et al.
The American Journal of Drug and Alcohol Abuse (2022) Vol. 48, Iss. 5, pp. 509-528
Closed Access | Times Cited: 14
Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample
Kirsten E. Smith, Jeffrey M. Rogers, Justin C. Strickland
Journal of Psychoactive Drugs (2021) Vol. 54, Iss. 5, pp. 429-439
Open Access | Times Cited: 13
What Is the Kratom Overdose Risk? A Systematic Literature Review
Corneliu N. Stanciu, Samantha A. Gnanasegaram, Gerald L. Rader, et al.
Current Addiction Reports (2023) Vol. 10, Iss. 1, pp. 9-28
Closed Access | Times Cited: 5
Use of Cannabinoids by People Who Consume Kratom in the United States
Katherine Hill, Oliver Grundmann, Leigh V. Panlilio, et al.
Journal of Addiction Medicine (2024) Vol. 18, Iss. 6, pp. 719-722
Closed Access | Times Cited: 1
Dynamic Topic Modeling of Kratom Use and Experiences: Insights on 13 years of Reddit Discussions
Seraphina Fong, Alessandro Carollo, Elisabeth Prevete, et al.
(2024)
Open Access | Times Cited: 1
Cannabinoid mechanisms contribute to the therapeutic efficacy of the kratom alkaloid mitragynine against neuropathic, but not inflammatory pain
Daniel Farkas, Saadet Inan, Laila N. Heydari, et al.
Life Sciences (2023) Vol. 328, pp. 121878-121878
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top